Soligenix Inc. Advances in Treating Rare Skin Cancer with HyBryte Platform

As the American population ages, the healthcare system faces increasing challenges from chronic and rare diseases, particularly among older adults. With over 30 million Americans living with a rare disease, the demand for accurate diagnoses and effective treatments is more urgent than ever. Many of these conditions lack FDA-approved therapies, and symptoms in seniors are often mistakenly attributed to normal aging, leading to prolonged diagnostic delays. In response to this crisis, initiatives like the Trump administration's "Make America Healthy Again" have focused on enhancing access to treatments and speeding up medical innovation.

Soligenix Inc. (NASDAQ: SNGX) is at the forefront of addressing this need with its HyBryte™ platform, a novel therapy designed to treat cutaneous T-cell lymphoma (CTCL), a rare skin cancer that predominantly affects older adults. The successful U.S.-based manufacturing of HyBryte's active ingredient marks a significant milestone for Soligenix, showcasing the potential of domestic innovation to make a substantial impact on this underserved patient population. This development not only highlights Soligenix's commitment to advancing healthcare solutions but also positions the company alongside other pharmaceutical giants such as Pfizer Inc. (NYSE: PFE), Merck & Co Inc. (NYSE: MRK), and Bristol-Myers Squibb Co. (NYSE: BMY) in the fight against rare diseases.

The progress of Soligenix's HyBryte platform is a testament to the importance of innovation in the pharmaceutical industry, especially in high-growth therapeutic areas. As the company continues to advance its pipeline, the potential for HyBryte to address a critical unmet medical need offers hope to patients and strengthens investor confidence in the sector. This development underscores the broader implications of medical innovation for improving patient outcomes and addressing the challenges posed by an aging population.